AZ/Merck & Co's Lynparza sets 'new standards' in ovarian can...

AstraZeneca and Merck & Co’s Lynparza should be the standard therapy for a certain group of ovarian cancer patients according to US cancer experts reviewing long-term trial data. 

AZ/Merck & Co's ovarian cancer drug gets wider US licence

AstraZeneca and Merck & Co have hit back at their rival GlaxoSmithKline after the FDA allowed Lynparza to be used in a wider group of ovarian cancer patients when combined with Roche’s

GSK takes fight to AZ/Merck & Co with first-line ovarian can...

The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against AstraZeneca and Merck & Co’s class

Epsilogen licenses first-in-class IgE ovarian cancer drug

AZ's cediranib falls short again in ovarian cancer combinati...

AstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it did not improve survival compared with chemotherapy in advanced ovarian cancer, in

NICE rejects Astellas' Xospata in AML, queries MSD's Keytrud...

NICE has been busy with announcements today, rejecting Astellas’ Xospata for a certain type of acute myeloid leukaemia (AML) and querying evidence for MSD's Keytruda in head and neck cancer